Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Total Assets
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) holds total assets worth CN¥2.40 Billion CNY (≈ $351.41 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hubei Biocause Heilen Pharmaceutical Co. net assets for net asset value and shareholders' equity analysis.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Total Assets Trend (2017–2024)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total assets have evolved over time, based on quarterly financial data.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total assets of CN¥2.40 Billion consist of 75.3% current assets and 24.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 21.8% |
| Accounts Receivable | CN¥80.68 Million | 3.2% |
| Inventory | CN¥137.85 Million | 5.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥68.94 Million | 2.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 301211 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s current assets represent 75.3% of total assets in 2024, an increase from 65.6% in 2017.
- Cash Position: Cash and equivalents constituted 21.8% of total assets in 2024, up from 9.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 8.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 5.5% of total assets.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Total Assets
Key competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.95 | 14.62 | 3.31 |
| Quick Ratio | 13.00 | 13.41 | 2.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.65 Billion | CN¥1.75 Billion | CN¥424.33 Million |
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.33 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | CN¥2.49 Billion |
| Market Capitalization | $702.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2024)
The table below shows the annual total assets of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.49 Billion ≈ $364.17 Million |
-2.27% |
| 2023-12-31 | CN¥2.55 Billion ≈ $372.64 Million |
+1.96% |
| 2022-12-31 | CN¥2.50 Billion ≈ $365.50 Million |
+7.18% |
| 2021-12-31 | CN¥2.33 Billion ≈ $341.00 Million |
+190.11% |
| 2020-12-31 | CN¥803.25 Million ≈ $117.54 Million |
+7.74% |
| 2019-12-31 | CN¥745.56 Million ≈ $109.10 Million |
+16.45% |
| 2018-12-31 | CN¥640.24 Million ≈ $93.69 Million |
+19.69% |
| 2017-12-31 | CN¥534.90 Million ≈ $78.27 Million |
-- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. The company is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. It also provides raw material products, including … Read more